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New markers are needed to improve diagnosis and to personalize treatments for patients with breast cancer (BC).
Receptor-interacting protein of 140 kDa (RIP140) and ligand-dependent corepressor (LCoR), two transcriptional co-
regulators of estrogen receptors, strongly interact in BC cells. Although their role in cancer progression has been
outlined in the last few years, their function in BC has not been elucidated yet. In this study, we investigated
RIP140 and LCoR localization (cytoplasm vs nucleus) in BC samples from a well-characterized cohort of patients
(n = 320). RIP140 and LCoR were expressed in more than 80% of tumors, (predominantly in the cytoplasm), and
the two markers were highly correlated. Expression of RIP140 and LCoR in the nucleus was negatively correlated
with tumor size. Conversely, RIP140 and LCoR cytoplasmic expression strongly correlated with expression of two
tumor aggressiveness markers: N-cadherin and CD133 (epithelial mesenchymal transition and cancer stem cell
markers, respectively). Finally, high RIP140 nuclear expression was significantly correlated with longer overall
survival, whereas high total or cytoplasmic expression of RIP140 was associated with shorter disease-free survival.
Our study strongly suggests that the role of RIP140 and LCoR in BC progression could vary according to their2Should be considered as co-first or co-last authors.
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involvement in BC progression/invasiveness of cytoplasmic RIP140 could be balanced by the anti-tumor action of
nuclear RIP140, thus explaining the previous contradictory findings about its role in BC.
Translational Oncology (2018) 11, 1090–1096Introduction
Breast cancer (BC) is the most frequent cancer and the leading cause
of mortality in women worldwide [1]. The involvement of nuclear
receptors in BC progression and aggressiveness is widely accepted.
Human epidermal growth factor receptor 2 (HER2), estrogen
receptor (ER) and progesterone receptor (PR) are key prognostic
and predictive markers, and their expression is routinely determined
in primary BCs [2]. Nuclear expression of ER/PR in tumor tissue is
correlated with good outcome and an expected sensitivity to
endocrine therapy, such as selective ER modulators (SERMs; e.g.,
tamoxifen). Conversely, HER2 expression is correlated with poor
prognosis in untreated patients with BC and an expected sensitivity to
the humanized anti-HER2 antibody trastuzumab [3].
The main nuclear receptor activities are precisely regulated through
complex and dynamic interactions of transcriptional co-regulators.
Several families of coactivators and corepressors are involved in the
development, progression, invasion, and therapy resistance of solid
tumors, especially hormone-responsive cancers, such as breast,
ovarian and prostate cancers [4,5]. Among the many nuclear receptor
co-regulators, Receptor Interacting Protein of 140 kDa (RIP140),
also called Nuclear Receptor Interacting Protein 1 (NRIP1), acts
predominantly as a corepressor [6–9] through recruitment of histone
deacetylase (HDAC) and C-terminal binding proteins (CtBPs)
[10,11]. RIP140 plays pivotal roles in normal cell metabolism,
especially in lipid metabolism [12,13], and is required for ovulation
and mammary gland development [14]. RIP140 could also function
as a tumor suppressor in ovarian and colon cancer. Specifically, in
ovarian cancer, RIP140 interacts mainly with ERβ and could be
involved in the repression of ERα activity by ERβ [15]. In colon
cancer, RIP140 inhibits cell proliferation through the Wnt signaling
pathway [16]. Similarly, it has been suggested that RIP140 is a
favorable prognostic marker in chronic lymphocytic leukemia [17]. In
BC, RIP140 acts as a coactivator of ERα-responsive genes, and might
regulate tumor progression and response to endocrine therapy [18].
On the other hand, RIP140 is the immediate downstream target of
nucleolar protein 14 (NOP14), an RNA binding protein that acts as a
tumor suppressor gene in BC through the Wnt/APC/βcatenin
pathway [9]. Moreover, RIP140 is overexpressed in BC cell lines and
tumors compared with normal breast cell lines and adjacent healthy
tissues [7,9]. Importantly, RIP140 expression is higher in the nucleus
of epithelial cells in malignant BC, whereas it is stronger in the
cytoplasm of stromal cells in benign tumors [7].
We recently demonstrated that RIP140 directly interacts with
Ligand-dependent CoRepressor (LCoR) and that the two proteins
colocalize in the nucleus of human BC cells. RIP140 positively
regulates LCoR expression and is necessary for LCoR-mediated
inhibition of gene expression and cell proliferation in BC cells [19].
LCoR is a nuclear protein that interacts with ERα and the repressive
activity of which is driven through HDAC and CtBPs recruitment, asdescribed for RIP140 [20–22]. LCoR shows repressive activity in BC
cells [19,23], and also inhibits prostate cancer growth in murine
models [24]. Moreover, high RIP140 and LCoR mRNA expression
were associated with longer survival in a cohort of 183 patients with
BC [19]. Very recently, a study confirmed the relevance of LCoR in
BC by demonstrating that it inhibits mammary cancer stem cell
(CSC) activity [25].
In this retrospective study, we wanted to determine the specific role
of nuclear and cytoplasmic RIP140 and LCoR expression in BC. To
this aim, we analyzed the tumor sub-cellular expression of these two
transcriptional co-regulators in a cohort of 320 patients with BC, and
evaluated the correlation with clinicopathological features and the
expression of tumor aggressiveness markers.
Materials and Methods
Patient Characteristics
For this study, a well characterized collection of paraffin-embedded
breast tumor tissue samples from 320 patients with BC was used. As
only eight patients had metastatic BC at the time of diagnosis, the
cohort was considered to be composed of patients with primary BC.
The study was approved by the Ethics Committee of the Ludwig
Maximilians University (LMU) of Munich, Germany (approval
number 048–08). BC tissue samples were collected from patients
treated for BC at the LMU Department of Obstetrics and
Gynecology between 2000 and 2002. All tumors were classified
using the tumor-node-metastasis (TNM) classification that includes
the tumor size (primary tumor size, or pT, as defined in the TNM
classification: pT1a-c, pT2, pT3, pT4a-d), the involvement of
regional lymph nodes (N), and presence or absence of metastases (M).
The BC histological grade was determined by an experienced
pathologist (Dr D. Mayr) of the LMU Department of Pathology,
according to the Elston and Ellis modification of the Bloom and
Richardson grading system [26]. Patient data, such as age, hormone
receptor status (ERα and PR), HER2-amplification, histological
grade, metastases, local recurrence, progression and survival, were
retrieved from the Munich Cancer Registry. The patients' character-
istics are shown in Table 1.
Immunohistochemistry
Expression of ERα, PR and HER-2 was determined in all BC
samples of this cohort at the LMU Department of Pathology,
Germany, at diagnosis. ERα and PR expression was evaluated by
immunohistochemistry, as described previously [26]). Samples
showing nuclear staining in more than 10% of tumor cells were
considered as hormone receptor-positive, in agreement with the
guidelines at the time of the analysis (2000–2002). HER2 expression
was analyzed with an automated staining system (Ventana; Roche,
Mannheim, Germany), according to the manufacturer's instructions.
Table 2. Correlation Between Total, Nuclear and Cytoplasmic Expression of RIP140 and LCoR
Correlation coefficient
n = 299 to 309
RIP140 LCoR
Total Nuclear Cytoplasmic Total Nuclear Cytoplasmic
RIP140 Total 1.000
Nuclear 0.793 ** 1.000
Cytoplasmic 0.874 ** 0.427 ** 1.000
LCoR
Total 0.414 ** 0.248 ** 0.459 ** 1.000
Nuclear 0.331 ** 0.284 ** 0.327 ** 0.819 ** 1.000
Cytoplasmic 0.397 ** 0.173 ** 0.465 ** 0.898 ** 0.536 ** 1.000
** P ≤ .01 (Spearman's rho test).




















Invasive lobular 42 13.1%
Invasive medullar 12 3.8%
Invasive mucinous 4 1.3%
No Special Type (NST) † 174 54.4%
DCIS (only or with NST) 83 25.9%
Unknown 5 1.6%
Tumor size *
pT1 a, b, c 205 64.1%
pT2 90 28.1%
pT3 4 1.3%



















* All data refer to the primary tumor.
† NST include the formerly called “Invasive ductal” and “other” types.
‡ Distant metastases were detected in 8 patients (2.5%) at diagnosis and in 59 patients during the follow-
up (18.44%).
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extracted from a previously published study [27]. For RIP140 and
LCoR analysis, samples were processed as previously described
[27,28]. Specifically, 3 μm tissue sections, cut from paraffin-
embedded BC samples, were dewaxed in xylol (Carl Roth GmbH
&Co. KG, Karlsruhe, Germany) at room temperature for 15 min. To
block endogenous peroxidases, sections were immersed in a solution
of 3% hydrogen peroxide (VWR International S.A.S., Fontenay-sous-
Bois, France) in methanol (Sigma-Aldrich, Steinheim, Germany) for
20 min. After rehydrating in decreasing concentrations of ethanol
(100–0% in distilled water), sections were boiled in a pressure cooker
with sodium citrate buffer (pH 6) for 5 min (for epitope retrieval).
Then, sections were washed with distilled water and phosphate
buffered saline (PBS), before blocking with Powerblock (Biogenex,
San Ramon, CA, USA) in distilled water (1:10) for 5 min. Sections
were then incubated with the rabbit polyclonal anti-NRIP1HPA046571 (1:400 in PBS; Sigma-Aldrich) and the mouse
polyclonal anti-LCoR NBP1–83477 antibody (1:50 in PBS; Novus
Biologicals, Littleton, CO, USA) at 4 °C for 16 hours. After
incubation with the corresponding biotinylated secondary anti-rabbit
and anti-mouse IgG antibodies, and with the associated avidin-biotin-
peroxidase-complex (both Vectastain Elite ABC Kit; Vector
Laboratories, Burlingame, CA, USA), interactions were visualized
with the substrate and chromogen 3,3-diamino-benzidine (Dako,
Glostrup, Denmark). Sections were counterstained with acidic
hematoxylin and dehydrated in increasing concentrations of ethanol
(70–100%). They were immediately mounted with Eukitt (Merck,
Darmstadt, Germany) before manual analysis with a Diaplan light
microscope (Leitz, Wetzlar, Germany) with 2.5x, 10x or 40x
magnification. Images were acquired with a digital CCD camera
system (JVC, Tokyo, Japan). Negative controls were performed by
replacing the primary antibodies with the species-specific isotype
control antibodies (Dako, Glostrup, Denmark). Appropriate positive
controls (placenta samples) were included in each experiment.
Data Analysis
For RIP140 and LCoR expression, the immunoreactive score (IRS)
was determined by evaluating the percentage of positive tumor cells
and their staining intensity (IRS = percentage score x intensity score).
For the quantification of positive cells (percentage score), BC samples
were classified in four groups: no visible staining (score = 0), b10% of
stained cells (score = 1), 10–50% of stained cells (score = 2), 51–80% of
stained cells (score = 3), and 81–100% of stained cells (score = 4).
Staining intensity (intensity score) was evaluated as: absence of staining
(score = 0), weak (score = 1), moderate (score = 2), or strong staining
(score = 3). Therefore, the maximum IRS value is 12. In doubtful cases,
slides were evaluated by two or three independent examiners and the IRS
represented the final consent. Staining localization (cytoplasmic and
nuclear) was evaluated in parallel, leading to the determination of the
cytoplasmic IRS and nuclear IRS separately. When needed, the total IRS
was calculated by adding the cytoplasmic and nuclear IRS. For N-
cadherin andCD133 expression, the IRS values corresponded to the total
expression (i.e., nuclear and cytoplasmic staining) [27].
Statistical Analysis
Statistical analyses were performed using SPSS 23 (IBMSPSS
Statistics, IBM Corp., Armonk, NY, USA). The correlations
presented in Tables 2 and 3 were obtained by calculating the Pearson
or Spearman's rho correlation coefficient (p values of Spearman's rho
presented). Data distribution was displayed using box and whisker
plots and the Kruskal-Wallis non-parametric one-way analysis of
variance was used to detect significant differences. The p value and
the number of patients/BC samples analyzed in each subgroup are




n = 179 to 304
LCoR
n = 185 to 309
Total Nuclear Cytoplasmic Total Nuclear Cytoplasmic
pT −0.134 * −0.181 ** −0.074 −0.134 * −0.149 ** −0.086
NCAD 0.116 0.049 0.137 * 0.258 ** 0.111 0.317 **
CD133 0.222 ** 0.155 * 0.201 ** 0.189 ** 0.107 0.198 **
* P ≤ .05 or

























Figure 1. Immunohistochemical analysis of RIP140 and LCoR
expression. Evaluation of RIP140 (A to D) and LCoR (E to H)
expression in primary BC samples showing no or low nuclear
expression (A, C, E, G) and high nuclear expression (B, D, E, F) of
the two transcription co-regulators. The cytoplasmic and nuclear
IRS values are indicated for each BC sample. Scale bars: 50 μm.
Translational Oncology Vol. 11, No. xx, 2018 RIP140 and LCoR expression in breast cancer Sixou et al. 1093given for each chart. For comparison of survival times, Kaplan–Meier
curves were generated. Mantel-Cox (log-rank) tests were performed to
compare survival curves (disease-free survival, DFS; or overall
survival, OS). For all analyses, p values below 0.05 were considered
statistically significant.
Results
RIP140 and LCoR Expression in BC Samples
The tumor samples evaluated for this study were from 320 patients
with BC (mean age 59.9 years, range 26–94 years) who were followed
for 10–12 years. As patients were treated between 2000 and 2002,
hormone receptor and HER2 status were not recorded for all of them
at the time of diagnosis (unknown ER and PR status in 19.5% and
unknown HER2 status in 37.1% of patients) (Table 1). Most
patients (n = 239; 74.7%) had a primary BC without metastases at
diagnosis, and 59 (18.44%) developed distant metastases during the
follow-up. Distant metastases were detected in 8 patients (2.5%)
already at diagnosis, and the metastasis status at diagnosis was
unknown in 14 patients (4.38%).
Analysis of RIP140 and LCoR expression in all BC samples showed
that 304 and 309 samples were positive for RIP140 and LCoR,
respectively. As staining was observed in the nucleus and/or
cytoplasm of tumor cells, the IRS was calculated for each subcellular
location (Figure 1). Some tumors displayed similar nuclear and
cytoplasmic IRS values for the same protein (Figure 1, A and E, and
B and F), whereas in other BC samples the nuclear and cytoplasmic
IRS values were very different (Figure 1, D and H, and C and G).
Analysis of the distribution of the nuclear and cytoplasmic IRS
values for RIP140 (Supplementary Fig. 1A and C) and LCoR
(Supplementary Fig. 1B and D) showed that the highest IRS values
was 9 in the nucleus and 8 in the cytoplasm for LCoR, whereas it was
6 in both compartments for RIP140. However, as very few samples had
very high LCoR IRS values, the mean IRS were similar for LCoR and
RIP140 (1.31 and 2.71 in the nucleus and cytoplasm respectively for
LCoR, and 1.71 and 2.12 respectively for RIP140). For both proteins, the
mean IRS was higher in the cytoplasm than in the nucleus.
Analysis of the correlations between nuclear, cytoplasmic and total
IRS for each protein independently using the Spearman rho (Table 2)
showed that for RIP140 (n = 304 samples), the total IRS was strongly
correlated with both nuclear and cytoplasmic IRS, and that the
nuclear and cytoplasmic IRS were correlated between them (P b .01).
Similar results were obtained for LCoR (n = 309) (P b .01).
The correlations between nuclear and cytoplasmic IRS values for
RIP140 and LCoR were confirmed also when BC samples were classified
in two groups based on the absence (IRS = 0) and presence (IRS N0) of
nuclear expression of RIP140 or LCoR (Supplementary Fig. 2A-B) (box
plots and Kruskal-Wallis non-parametric test, P b .001).Correlation Between RIP140 and LCoR Expression
Concerning the total expression of RIP140 and LCoR, both
transcription co-regulators were negative (IRS = 0) in 1.7% of BC
samples (Figure 2), whereas they were both positive (IRS N0) in
81.3% of tumors. Positivity for only one was detected in 17% of
samples. A similar distribution was observed for the nuclear and
cytoplasmic IRS values. More than 60% of tumor samples expressed
Figure 2.Distribution of RIP140 and LCoR expression in primary BC
samples. The graph shows the percentage of tumors expressing
both proteins, only RIP140, only LCoR, or none (IRS = 0).
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of tumors were negative for both RIP140 and LCoR.
In agreement, the total, cytoplasmic and nuclear IRS for RIP140
were positively and significantly correlated with the relevant IRS
values for LCoR (P b .01, n = 299 samples with both stainings)




Figure 3. Kaplan–Meier analysis of patient survival according to the R
values for low and high RIP140 or LCoR expression were determined
nuclear RIP140 IRS N2 (A). Disease-free survival (12-year follow-up) ac
free survival was associated with total LCoR IRS values only in the svalues for RIP140 and LCoR was confirmed when BC samples were
classified in two groups based on the absence (IRS = 0) and presence
(IRS N0) of nuclear or cytoplasmic expression of LCoR (Supplemen-
tary Fig. 2C-D) (box plots and Kruskal-Wallis non-parametric test,
P b .001). Similar results were obtained for the total IRS values
(data not shown).
Correlation of RIP140 and LCoR Expression with Clinico-
pathological Parameters and Tumor Aggressiveness Markers
Expression of ER and PR (two main prognostic markers for BC)
did not correlate with RIP140 or LCoR expression (total, cytoplasmic
or nuclear IRS values, data not shown). Conversely, the total
(P b .05) and nuclear (P b .01) IRS values for RIP140 and LCoR
were negatively correlated with pT (Table 3). This result was
confirmed after separating BC samples in two groups based on the
pT: pT1 (tumor size ≤20 mm at its widest area) and pT2–4 (tumor
larger than 20 mm) (Supplementary Fig. 3A-B).
No other clinicopathological parameter (age, HER2, histologic
type, grade, node status, distant metastases, triple negative status,
contralateral BC and local recurrence) was correlated with RIP140 or
LCoR expression (data not shown). However, in the specific
subgroup of patients with nuclear expression of both RIP140 and
LCoR (n = 188), nuclear RIP140 was negatively correlated with ERα





IP140 or LCoR IRS values. For this analysis, optimized IRS cut-off
by ROC-curve analysis. Overall survival was longer in patients with
cording to total (B) or cytoplasmic (C) RIP140 IRS values. Disease-
ub-population of patients with HER2-positive BC (n = 94) (D).
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P b .01).
Besides these widely used clinicopathological features, BC
aggressiveness is known to be driven by other parameters, such as
epithelial mesenchymal transition (EMT) and CSCs. N-cadherin
(EMT marker) and CD133 (CSC marker) expression correlated with
cytoplasmic RIP140 (P b .05 for N-cadherin and P b .01 for
CD133) and cytoplasmic LCoR expression (P b .01 for N-
cadherin and for CD133), and also with total LCoR (P b .01).
Moreover, CD133 correlated also with nuclear and total IRS for
RIP140 (P b .01) (Table 3).
The correlations between cytoplasmic RIP140/LCoR and N-
cadherin (Supplementary Fig. 3C-D) and CD133 expression
(Supplementary Fig. 3E-F) were confirmed after grouping the BC
samples according to the presence (IRS N0) and absence (IRS = 0) of
N-cadherin or CD133 expression, respectively. Moreover, in the
whole cohort, N-cadherin was correlated with CD133 expression
(rho = 0.432, n = 261, P b .01).
Correlation with patient survival
Kaplan–Meier analyses identified significant correlations between
RIP140 and LCoR expression and DFS and OS (Figure 3). For this
analysis, optimized IRS cut-off values for low and high RIP140 or
LCoR expression were determined by receiver operating characteristic
curve (ROC-curve) analysis, based on the maximal differences of
sensitivity and specificity.
Patients with tumors with low nuclear RIP140 expression (IRS ≤2)
had a worse OS than those with high IRS values (IRS N2) (mean OS:
9.37 ± 0.30 years vs 10.14 ± 0.38 years; P = .041). Conversely,
DFS was significantly longer in patients with low total RIP140
expression (IRS ≤4) than in those with high expression (IRS N4)
(mean DFS: 8.15 ± 0.39 years vs 6.89 ± 0.51 years; P = .046)
(Figure 3, A and B). A similar trend, although not significant, was
observed for cytoplasmic RIP140 expression (P = .056, Figure 3C).
LCoR expression did not have a significant effect on DFS or OS in
the whole population. However, within the subgroup with HER2-
positive tumors (n = 94), DFS was significantly longer in patients
with low (total IRS ≤1) than in those with higher LCoR expression
(total IRS N1) (mean DFS: 9.38 ± 0.77 years vs 6.23 ± 0.52 years;
(P = .013)(Figure 3D).
Finally, multivariate analysis using the Cox regression model with
RIP140 and LCoR expression (total, nuclear or cytoplasmic), N-
Cadherin and CD133 levels and 11 clinicopathological features (ER,
PR, HER2, triple negative status, histologic type, age, grading, pT,
pN, local recurrence, and distant metastases) showed that besides age,
pT, pN, and distant metastasis, no other parameter was an
independent prognostic factor for OS in this cohort (data not shown).
Discussion
The purpose of this study was to elucidate the expression localization of
the two transcription co-regulators RIP140 and LCoR in BC, and to
correlate their expression in different cell compartments with tumor
aggressiveness markers, clinicopathological features and patient survival.
Both RIP140 and LCoR were expressed in most of the 320 BC
samples analyzed. Overall, they were moderately expressed, and
predominantly in the cytoplasm with a strong correlation between
cytoplasmic and nuclear expression for each protein. We and others
previously described their expression in both nucleus and in
cytoplasm [7,19,29]. Aziz et al. [7] reported a preferential increaseof RIP140 nuclear localization in epithelial cancer cells. Various post-
translational modifications, including lysine acetylation [30] or
conjugation to vitamin B6 [31], have been proposed to explain
RIP140 nucleo-cytoplasmic shuttling. Fewer data are available
concerning LCoR post-translational modifications and it should be
interesting to monitor its phosphorylation status, particularly in
HER2-positive BC in view of our findings (see data from Figure 3D). In
theMCF-7 cell line used as a ER/PR-positive BCmodel, LCoR is evenly
distributed in both compartments, whereas RIP140 is expressed
predominantly in the nucleus [19]. Therefore, the MCF7 cell line, like
the tumors of our patient cohort, is characterized by a low cytoplasmic/
nuclear IRS ratio for RIP140 and a ratio close to 1 for LCoR.
By comparing the expression of both RIP140 and LCoR, we found
strong correlations between their cytoplasmic, nuclear and total
expression. More than 80% of tumors expressed both proteins,
whereas only 1.7% was negative for both. For both RIP140 and
LCoR, the mean IRS values were higher in the cytoplasm than in the
nucleus. These results are fully concordant with our previously
published data obtained by mRNA analysis and showing that RIP140
can transactivate the LCOR gene promoter in BC cells [19].
We then analyzed the correlations between expression of RIP140/
LCoR and of N-cadherin (EMT marker) and CD133 (CSC marker).
We previously demonstrated that N-cadherin and CD133 expression
correlate positively in 307 primary BC tumors from this cohort, and
that N-cadherin positivity is associated with shorter survival time for
patients without lymph node metastases [27]. Moreover, N-cadherin
expression was significantly higher in metastases than in the related
primary tumors. Here, we found that RIP140 and LCoR cytoplasmic
expression were positively correlated with N-cadherin and CD133
expression, suggesting that in the cytoplasm, RIP140 and LCoR could
specifically interact with these pathways to promote BC progression.
Analysis of the correlations between the patients' clinicopatholog-
ical and RIP140 and LCoR IRS values highlighted that only tumor
size was negatively correlated with nuclear RIP140 and LCoR
expression, suggesting that nuclear RIP140 and LCoR may play a role
in tumor growth inhibition. Moreover, nuclear RIP140 was
negatively correlated with ERα and PR and positively correlated
with the triple negative status in the subgroup of patients with nuclear
expression of both RIP140 and LCoR.
Altogether, these findings suggest that RIP140 and LCoR may
have different roles in tumor development according to their
subcellular location. This hypothesis is supported by the results of
our survival analyses. Indeed, high total or cytoplasmic expression of
RIP140 was associated with shorter DFS, whereas high nuclear
expression predicted longer OS. This suggests opposite roles for
cytoplasmic and nuclear RIP140 in survival. Similarly, low total
LCoR expression was strongly correlated with longer DFS in patients
with HER2-positive cancer. A previous study demonstrated that low
RIP140 or LCOR mRNA expression is associated with poor OS [19].
Although RIP140 and LCoR expression are well correlated with
each other in BC samples, the present study also demonstrates that
these two transcription co-regulators may play different roles in breast
tumorigenesis, according to their subcellular location. Indeed, nuclear
RIP140 correlated with smaller tumor size and longer OS, whereas
cytoplasmic LCoR correlated with markers of poor prognosis (N-
cadherin, CD133) and poor DFS in HER2-positive tumors.
However, the result of the multivariate analysis indicated that only
age, pT, pN, and distant metastasis are independent prognostic
factors for OS in this cohort. Therefore, further studies are needed to
1096 RIP140 and LCoR expression in breast cancer Sixou et al. Translational Oncology Vol. 11, No. xx, 2018delineate the specific roles of cytoplasmic and nuclear RIP140 and
LCoR in BC progression as well as their relevance as potential new
independent prognostic markers in BC. Especially, it would be
relevant to investigate the involvement the association of nuclear and
cytoplasmic expression of RIP140 and LCoR with the response of BC
patients to systemic or targeted therapies.
It is however noteworthy to highlight that, in this first study dealing
with the specific analysis of nuclear/cytoplasmic expression of RIP140 and
LCoR in breast tumors, data showing correlations of expression with
patient survival or other parameter such as tumor size or expression of
CD133/N-Cadherin, is helpful to better appreciate the biological roles of
these two transcriptional co-regulators in breast tumorigenesis.
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